Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03914742 · ClinicalTrials.gov registry record · Phase 1
BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
A Phase 1 study of Recurrent Glioblastoma and Recurrent WHO Grade III Glioma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
- 12
- Study locations
NCT03914742 is a Phase 1 study of Recurrent Glioblastoma and Recurrent WHO Grade III Glioma that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 67 participants, roughly in line with the 68-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target. The trial reports 12 study locations across 11 states.
The verdict
NCT03914742, a Phase 1 study of Recurrent Glioblastoma and Recurrent WHO Grade III Glioma, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
- 12
- Study locations
Study Summary
This phase I/II trial studies the side effects and how well BGB-290 and temozolomide work in treating patients with gliomas (brain tumors) with IDH1/2 mutations that have come back. BGB-290 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BGB-290 and temozolomide may work better in treating patients with recurrent gliomas.
Conditions Studied
Interventions
- DRUG Temozolomide
- PROCEDURE Therapeutic Conventional Surgery
- DRUG PARP Inhibitor BGB-290
Study Locations (12)
Pennsylvania
- University of Pennsylvania - Philadelphia
- Hillman Cancer Center at University of Pittsburgh Cancer Institute - Pittsburgh
Alabama
- UAB Comprehensive Cancer Center - Birmingham
California
- University of California, Los Angeles - Los Angeles
Connecticut
- Yale University - New Haven
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- Josephine Ford Cancer Center at Henry Ford Hospital - Detroit
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2020-02-16 |
| Est. Completion | 2023-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03914742
The ClinicalTrials.gov registry entry for NCT03914742 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 68-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Recurrent Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Temozolomide is the first listed.
NCT03914742 reports 12 study locations spanning 11 distinct geographic areas - top geographies include Pennsylvania, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT03914742 about?
NCT03914742 is a clinical study titled "BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations". This phase I/II trial studies the side effects and how well BGB-290 and temozolomide work in treating patients with gliomas (brain tumors) with IDH1/2 mutations that have come back. BGB-290 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemo...
What is the current status of trial NCT03914742?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2020-02-16. Estimated completion is 2023-10-31.
What conditions does trial NCT03914742 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma, Recurrent WHO Grade III Glioma, IDH1 Mutation, Recurrent WHO Grade II Glioma, IDH2 Mutation.
What interventions are being tested in trial NCT03914742?
The interventions under investigation include: Temozolomide (DRUG), Therapeutic Conventional Surgery (PROCEDURE), PARP Inhibitor BGB-290 (DRUG).
Who is sponsoring clinical trial NCT03914742?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03914742 being conducted?
This trial has 12 study locations across Alabama, California, Connecticut, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM
RECRUITING · Phase 1
-
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
RECRUITING · Phase 1
-
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
RECRUITING · Phase 1
-
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.